{"id":"W2594728560","doi":"10.2337/dc16-0984","title":"Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide","year":2017,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"ca_institutions":"Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Dulaglutide; Medicine; Sitagliptin; Exenatide; Placebo; Internal medicine; Gastroenterology; Acute pancreatitis; Insulin glargine; Type 2 diabetes; Metformin; Diabetes mellitus; Hypoglycemia; Endocrinology; Insulin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01038653,0.0004160275,0.0008049645,0.0005137745,0.0002300895,0.0007185428,0.0004866644,0.0006866307,0.001761268],"category_scores_gemma":[0.009623758,0.0002719349,0.0007190693,0.0003771621,0.0002608977,0.0007334159,0.0005440978,0.0007285856,0.0002954626],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004028318,"about_ca_system_score_gemma":0.0007262013,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000213008,"about_ca_topic_score_gemma":0.0002411971,"domain_scores_codex":[0.9931388,0.004485544,0.0003692193,0.0005540302,0.001275936,0.0001763577],"domain_scores_gemma":[0.9918891,0.002035869,0.004041174,0.0006685772,0.0007616729,0.0006036515],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.2830869,0.007703276,0.2494515,0.00112718,0.001952609,0.0002065243,0.0002684337,0.002764589,0.03559553,0.0002519115,0.001182742,0.4164089],"study_design_scores_gemma":[0.03883014,0.5442864,0.3697143,0.0001757767,0.00225049,0.001016837,0.0002050688,0.005995526,0.03037047,0.0002839435,0.00681782,0.00005312648],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9905814,0.003357672,0.00231497,0.0001397071,0.00003883343,0.001217246,0.0006070311,0.00008020135,0.001662912],"genre_scores_gemma":[0.9961481,0.0005392216,0.001740396,0.000128786,0.00004619433,0.0004939171,0.0003809962,0.000009519184,0.0005129405],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01038653,"threshold_uncertainty_score":0.05492991,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01776490638318756,"score_gpt":0.3043594013106409,"score_spread":0.2865944949274533,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}